Please login to the form below

Not currently logged in
Email:
Password:

Biohaven Pharmaceuticals

This page shows the latest Biohaven Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

Biohaven gets FDA approval for migraine drug Nurtec ODT

Biohaven gets FDA approval for migraine drug Nurtec ODT

Biohaven Pharma has become the second drugmaker to bring an oral CGRP inhibitor to the US market for acute migraine, after the US Food and Drug Administration (FDA) approved its Nurtec ... Biohaven says Nurtec ODT (rimegepant) – its first commercial

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    1. Rimegepant from BioHaven Pharmaceuticals is an antagonist of calcitonin gene-related peptide (CGRP), recently approved in the US for the acute treatment of migraine, with prevention trials also ongoing. ... Eli Lilly/Dong Pharmaceuticals’ 5-HT1f

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Menopause-thumbnail.png
Breaking the silence: It’s time to talk about the menopause
Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
Committing time to making meaningful connections - top 5 tips
Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
News:
Senior Analytics Specialist joins Research Partnership...